BioTelemetry has been granted approval by the Food and Drug Administration for its next-generation Mobile Cardiac Outpatient Telemetry device, writes John George for Philadelphia Business Journal.
The Malvern based wireless medical technology company’s new device, MCOT Patch, is designed for remote arrhythmia detection and was developed in partnership with Belgium’s IMEC. The system incorporates the proprietary patch technology acquired by the company in its recent $6 million acquisition of the ePatch division of Delta Danish Electronics, Light and Acoustics.
Joseph H. Capper, BioTelemetry’s president and CEO, said the new patch integrates the irregular heart detection capability of the existing MCOT system into a lightweight, easy-to-use form. The company believes that this simpler design will lead to more patients using the device.
“Moreover, due to its advanced capabilities and flexible design, our new sensor is also anticipated to have commercially viable applications in other areas of health care,” said Capper. “The introduction of the new system demonstrates our ongoing commitment to reaching as many patients as possible with our life-saving technology and service.”
BioTelemetry, which previously operated as CardioNet, expects to have the MCOT Patch commercially available later this year.
Read more about the new device at Philadelphia Business Journal here, and check out previous VISTA Today coverage of BioTelemetry here.
